Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study

Abstract Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavim...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 76; no. 8; pp. 1500 - 1503
Main Authors Birabaharan, Morgan, Hill, Eddie, Begur, Maedha, Kaelber, David C, Martin, Thomas C S, Mehta, Sanjay R
Format Journal Article
LanguageEnglish
Published US Oxford University Press 17.04.2023
Subjects
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Cohort Studies
COVID-19 - prevention & control
Humans
Pre-Exposure Prophylaxis
cilgavimab
cardiovascular
COVID 19
evusheld
tixagevimab
Online AccessGet full text

Cover

More Information
Summary:Abstract Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1058-4838
1537-6591
1537-6591
DOI:10.1093/cid/ciac894